LONDON -- A 6.8 million [pounds sterling] (US$12.3 million) fine against Genzyme Corp.'s UK subsidiary related to its Gaucher's disease treatment Cerezyme has been slashed on appeal to 3 million [pounds sterling], plus interest.
In its appeal Genzyme argued that the size of the original fine could undermine orphan drug research in new drugs for rare diseases.
The UK Competition Appeal Tribunal (CAT) upheld the main finding of the original judgment from April, which said that in pricing Cerezyme to include home delivery and home-infusion services, Genzyme was preventing competitors from buying the drug from a distributor and offering the same services.
CAT …
No comments:
Post a Comment